*

BDR 54-344
AB 186

EXECUTIVE AGENCY

FISCAL NOTE

AGENCY'S ESTIMATES

Date Prepared: April 30, 2025

Agency Submitting: Department of Health and Human Services, Health Care Financing and Policy

Items of Revenue or Expense, or Both	Fiscal Year 2024-25	Fiscal Year 2025-26	Fiscal Year 2026-27	Effect on Future Biennia
Medical Services (Expense) (Expense)		$803,367	$858,891	$1,717,782
Systems Cost (Expense) (Expense)		$11,200		
Personnel Services (Expense) (Expense)		$82,048	$110,718	$221,436
Personnel Services (Professionals) (Expense) (Expense)		$155,276	$203,919	$407,838
In-State Travel (Expense) (Expense)		$429	$572	$1,144
Operating (Expense) (Expense)		$6,591	$8,966	$17,932
Equipment (Expense) (Expense)		$6,646		
Information Services (Expense) (Expense)		$5,649	$2,971	$5,942
Training (Expense) (Expense)		$1,504	$1,504	$3,008
Total	0	$1,072,710	$1,187,541	$2,375,082

Explanation (Use Additional Sheets of Attachments, if required)

The Division has determined that the bill, if enacted, would have a fiscal impact. This bill would expand the scope of practice of a pharmacist to prescribe and dispense drugs and devices for the treatment of health conditions under certain specifications described in Section 1. This bill also expands the abilities of a pharmacist to perform CLIA waived laboratory tests and removes the limitation on pharmacists to use only fingerstick or oral or nasal swab to collect specimens. This fiscal impact, therefore, includes the subset of CLIA waived tests not currently covered and the cost of increased and expanded services, when such tests and services are performed by a pharmacist.

The fiscal analysis utilizes rates paid to physician assistants currently. A ramp-up period of 18 months was included due to the State's provider shortages and federal approval timelines. By the end of the ramp up period, an additional 65% of select laboratory services and medicine evaluation and management services are assumed to be billed by pharmacists, instead of physicians. A savings of $1,691,491 for SFY26/27 biennium is assumed due to the rate differential between physicians and pharmacists for these services. A portion of these costs would be used to fund additional administrative costs associated with these changes, including a Pharmacist II and Program Officer II for the increased need for capacity at the Division to monitor pharmacy billing compliance, as well as $2,800 General Fund expenditures in systems-related costs.

In sum, the Division estimates the bill would result in a total of $296,752 in new costs to the State General Fund for SFY26 and $287,774 for SFY27, with $2,053,853 being available in federal matching funds via Title XIX of the Social Security Act.

Name Stacie Weeks

Title Administrator

GOVERNOR'S OFFICE OF FINANCE COMMENTS

Date Thursday, April 24, 2025

The agency's response appears reasonable.

Name Tiffany Greenameyer

Title Director

FN 3838

Fiscal Impact Analysis

Division of Health Care Financing and Policy
AB 186 PT 91 Pharmacist Expansion of Scope
Analysis Summary

Estimated Fiscal Impact FY24-FY25 Biennium

State Fiscal Year	Total Computable	Federal Funds	General Fund	County Funds
FY24	$0	$0	$0	$0
FY25	$0	$0	$0	$0
Total	$0	$0	$0	$0

Estimated Fiscal Impact FY26-FY27 Biennium

State Fiscal Year	Total Computable	Federal Funds	General Fund	County Funds
FY26	$803,367	$602,448	$203,699	($2,780)
FY27	$858,891	$696,639	$174,429	($12,177)
Total	$1,662,258	$1,299,087	$378,128	($14,957)

Assumed Utilization **65%**

Description of Budget Concept

This bill would expand the scope of practice of a pharmacist to prescribe and dispense drugs and devices for the treatment of health conditions under certain specifications described in Section 1. This bill also expands the abilities of a pharmacist to perform CLIA waived laboratory tests and removes the limitation on pharmacists to use only fingerstick or oral or nasal swab to collect specimens. This fiscal impact, therefore, includes the subset of CLIA waived tests not currently covered and the cost of increased and expanded services, when such tests and services are performed by a pharmacist.

Methodology

1) Fee-For-Service (FFS) utilization (DSS Rpt) and Managed Care Encounter (DW Rpt) were captured by running reports out of the MMIS using the following parameters for this provider type/service: SFY24 (07/01/2023 - 06/30/2024) Incurred with Runoff, PT 77 PA, Visits Patient, Patients, Service Count Paid, Net Payment, Allowed Amount-Includes All Codes that are billable by a PT 77 Physician Assistant

2) Patient by Category counts were captured by running a report out of the MMIS to include FFS patients and Managed Care (MCO) patients.

3) Assume expanded Pharmacist services will match utilization and codes of Physician Assistants for FY2024.
4) Total computable expenditures are grown forward based on the DHHS Office of Analytics caseload projections.

5) FMAP rates were applied to determine the federal share of estimated costs.

State and Federal Shares - AB186

	Total			General Fund			Authorized Funds		
	FY26	FY27	Biennium	FY26	FY27	Biennium	FY26	FY27	Biennium
Medical Services	$803,367	$858,891	$1,662,258	$203,699	$174,429	$378,128	$803,367	$858,891	$1,662,258
Actuarial Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0
Systems Costs	$11,200	$0	$11,200	$2,800	$0	$2,800	$8,400	$0	$8,400
Vendor Support	$0	$0	$0	$0	$0	$0	$0	$0	$0
MCO Contract	$0	$0	$0	$0	$0	$0	$0	$0	$0
Personnel Services	$82,048	$110,718	$192,766	$41,024	$55,359	$96,383	$41,024	$55,359	$96,383
Personnel Services (Professionals)	$155,276	$203,919	$359,195	$38,819	$50,980	$89,799	$116,457	$152,939	$269,396
In-State Travel	$429	$572	$1,001	$215	$286	$501	$215	$286	$501
Operating	$6,591	$8,966	$15,557	$3,296	$4,483	$7,779	$3,296	$4,483	$7,779
Equipment	$6,646	$0	$6,646	$3,323	$0	$3,323	$3,323	$0	$3,323
Information Services	$5,649	$2,971	$8,620	$2,825	$1,486	$4,310	$2,825	$1,486	$4,310
Training	$1,504	$1,504	$3,008	$752	$752	$1,504	$752	$752	$1,504
Total	$1,072,710	$1,187,541	$2,260,251	$296,752	$287,774	$584,526	$979,658	$1,074,196	$2,053,853